Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Net product revenues by geography
Net product revenues by geography — United States (U.S.) ($M) ($M)
Vertex Pharmaceuticals Net product revenues by geography: $2,056M in Q2 2026, up 11.3% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Segment & Geographic Information Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net product revenues by geography — United States (U.S.) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2,056 | +11.3% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,776 | +6.8% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,091 | +13.8% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,976 | +15.3% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,848 | +14.5% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,664 | +9.4% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,837 | +16.7% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,714 | +10.2% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,614 | +7.1% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,520 | +8.3% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,575 | +7.8% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,554 | +6.8% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,508 | +6.6% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,404 | +2.6% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,460 | +4.8% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,456 | +5.3% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,415 | +12.6% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,368 | +9.2% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,394 | +15.6% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,383 | +13.1% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,257 | +3.9% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,253 | +5.5% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,206 | +19.6% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,223 | +72.1% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,210 | +72.8% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,188 | +85.2% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,008 | +48.9% | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2019 | Sep 30, 2019 | 710 | +14.5% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 701 | +19.8% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 641 | +32.8% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 677 | +34.6% | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2018 | Sep 30, 2018 | 621 | +36.5% | Form 10-Q (filed 2019-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | 585 | +36.1% | Form 10-Q (filed 2019-08-01) ↗ |
| Q1 2018 | Mar 31, 2018 | 483 | -19.4% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 503 | – | Form 10-K (filed 2020-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 455 | – | Form 10-Q (filed 2018-10-25) ↗ |
| Q2 2017 | Jun 30, 2017 | 430 | – | Form 10-Q (filed 2018-07-26) ↗ |
| Q1 2017 | Mar 31, 2017 | 599 | – | Form 10-Q (filed 2018-04-27) ↗ |
Breakdown
What makes up net product revenues by geography
Cite this data
StockData. (2026). Vertex Pharmaceuticals Net product revenues by geography ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rev-geo-hdr
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.